In experimental models, the combination of AZD5438 and PD0325901 not only outperformed either monotherapy in suppressing tumor growth but also augmented CD8+ T cell-mediated antitumor immunity by promoting caspase-8/gasdermin E-dependent pyroptosis. Here, CD8A is linked to neoplasm.